Advertisement

Digestive Diseases and Sciences

, Volume 64, Issue 4, pp 985–992 | Cite as

Liver Allocation Policies in the USA: Past, Present, and the Future

  • Anjana Pillai
  • Thomas Couri
  • Michael CharltonEmail author
Review
  • 92 Downloads

Abstract

Identifying the optimal allocation policy with regard to hepatocellular carcinoma has been a persistent and evolving challenge. The current criteria for LT for HCC endorsed by the United Network of Organ Sharing (UNOS) are based on the Milan Criteria: a solitary tumor < 5 cm, or maximum of three tumors ≤ 3 cm each, without vascular invasion or evidence of extrahepatic spread. Contraindications to HCC exception points include: stage 1 HCC, ruptured HCC, extrahepatic HCC, and main portal or hepatic vein HCC invasion. Based upon projected waitlist dropout rates due to tumor growth, patients with HCC are assigned MELD standardized exception points. In addition to tumor size and number, AFP levels are an important predictor of recurrence of HCC following liver transplantation. Standardized exception points for HCC patients are not awarded to patients with AFP levels > 1000 ng/mL that do not decrease to < 500 ng/mL with treatment. Appeals for MELD exception points for patients with HCC vary widely between UNOS regions, with success of nonstandardized exception point appeals varying from 3.1 to 21% between regions. In an effort to make prioritization for HCC more consistent, a national liver review board (NLRB)is being convened that will focus on developing a national guidance for assessing common requests and addressing exception points, including for HCC.

Keywords

Hepatocellular carcinoma Liver transplantation Policy Allocation 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391:1301–1314.CrossRefGoogle Scholar
  2. 2.
    Grandhi MS, Kim AK, Ronnekleiv-Kelly SM, Kamel IR, Ghasebeh MA, Pawlik TM. Hepatocellular carcinoma: from diagnosis to treatment. Surg Oncol. 2016;25:74–85.CrossRefGoogle Scholar
  3. 3.
    Rude MK, Crippin JS. Liver transplantation for hepatocellular carcinoma. Curr Gastroenterol Rep. 2015;17:11.CrossRefGoogle Scholar
  4. 4.
    Wedd J, Nordstrom E, Nydam T, et al. Hepatocellular carcinoma in patients listed for liver transplantation: current and future allocation policy and management strategies for the individual patient. Liver Transpl. 2007;13:465–466.Google Scholar
  5. 5.
    Mazzaferro V, Regalia E, Doci R, et al. Liver Transplantaiton for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693–699.CrossRefGoogle Scholar
  6. 6.
    Iwatsuki S, Starzl TE, Sheahan DG, et al. Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg. 1991;214:221–228.CrossRefGoogle Scholar
  7. 7.
    Ringe B, Wittekind C, Bechstein WO, Bunzendahl H, Pichlmayr R. The role of liver transplantation in hepatobiliary malignancy: a retrospective analysis of 95 patients with particular regard to tumor stage and recurrence. Ann Surg. 1989;209:88–98.CrossRefGoogle Scholar
  8. 8.
    Starzl TE, Marchioro TL, Von KK, et al. Homotranspantation of the liver in humans. Surg Gynecol Obstet. 1963;1963:659–676.Google Scholar
  9. 9.
    Deshpande R, Hirose R, Mulligan D. Liver allocation and distribution: time for a change. Curr Opin Organ Transpl. 2017;22:162–168.CrossRefGoogle Scholar
  10. 10.
    Klintmalm GB. Who should receive the liver allograft: the transplant center or the recipient? Liver Transpl Surg. 1995;1:55–58.CrossRefGoogle Scholar
  11. 11.
    Coombes JM, Trotter JF. Development of the allocation system for deceased donor liver transplantation. Clin Med Res. 2005;3:87–92.CrossRefGoogle Scholar
  12. 12.
    Lucey MR, Brown KA, Everson GT, et al. Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases [see comments]. Liver Transpl Surg. 1997;3:628–637.CrossRefGoogle Scholar
  13. 13.
    Kalra A, Wedd JP, Biggins SW. Changing prioritization for transplantation: MELD-Na, hepatocellular carcinoma exceptions, and more. Curr Opin Organ Transpl. 2016;21:120–126.CrossRefGoogle Scholar
  14. 14.
    Infante-Rivard C, Esnaola S, Villeneuve J-P. Clinical and statistical validity of conventional prognostic factors in predicting short-term survival among cirrhotics. Hepatology. 1987;7:660–664.CrossRefGoogle Scholar
  15. 15.
    Schilsky ML, Moini M. Advances in liver transplantation allocation systems. World J Gastroenterol. 2016;22:2922–2930.CrossRefGoogle Scholar
  16. 16.
    Roayaie KFS. Allocation policy for hepatocellular carcinoma in the MELD Era: Room for improvement? Liver Transpl. 2007;13:465–466.CrossRefGoogle Scholar
  17. 17.
    Fraley DS, Burr R, Bernardini J, Angus D, Kramer DJ, Johnson JP. Impact of acute renal failure on mortality in end-stage liver disease with or without transplantation. Kidney Int. 1998;54:518–524.CrossRefGoogle Scholar
  18. 18.
    Services D of H and H. Organ procurement and transplantation network: final rule with comment period. Fed Regist. 1998;63:16296–16338.Google Scholar
  19. 19.
    Kalra A, Biggins SW. New paradigms for organ allocation and distribution in liver transplantation. Curr Opin Gastroenterol. 2018;34:123–131.Google Scholar
  20. 20.
    Procurement O, Policies AC, Impact P, Final D, Committee R, Procurement O, et al. Organ Procurement and transplantation: assessing current policies and the potential impact of the DHHS final rule committee on organ procurement and transplantation policy. Institute of Medicine [Internet]; vol. 254, pp 0-309; 1999. Available from: http://www.nap.edu/catalog/9628.html.
  21. 21.
    Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, Ter Borg PCJ. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology. 2000;31:864–871.CrossRefGoogle Scholar
  22. 22.
    Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001;33:464–470.CrossRefGoogle Scholar
  23. 23.
    McDiarmid SV, Anand R, Lindblad AS. Development of a pediatric end-stage liver disease score to predict poor outcome in children awaiting liver transplantation. Transplantation. 2002;74:173–181.CrossRefGoogle Scholar
  24. 24.
    Barbara L, Benzi G, Gaiani S, et al. Natural history of small untreated hepatocellular carcinoma in cirrhosis: a multivariate analysis of prognostic factors of tumor growth rate and patient survival. Hepatolog [Internet]. 1992;16:132–137.CrossRefGoogle Scholar
  25. 25.
    Cheng SJ, Freeman RB, Wong JB. Predicting the probability of progression-free survival in patients with small hepatocellular carcinoma. Liver Transpl. 2002;8:323–328.CrossRefGoogle Scholar
  26. 26.
    Sharma P, Balan V, Hernandez JL, et al. Liver transplantation for hepatocellular carcinoma: the MELD impact. Liver Transpl. 2004;10:36–41.CrossRefGoogle Scholar
  27. 27.
    Wiesner RH, Freeman RB, Mulligan DC. Liver transplantation for hepatocellular cancer: the impact of the MELD allocation policy. Gastroenterology. 2004;127:261–267.CrossRefGoogle Scholar
  28. 28.
    Freeman RB, Wiesner RH, Edwards E, Harper A, Merion R, Wolfe R. Results of the first year of the new liver allocation plan. Liver Transpl. 2004;10:7–15.CrossRefGoogle Scholar
  29. 29.
    Yao FY, Bass NM, Nikolai B, et al. Liver transplantation for hepatocellular carcinoma: analysis of survival according to the intention-to-treat principle and dropout from the waiting list. Liver Transpl [Internet]. 2002;8:873–883.CrossRefGoogle Scholar
  30. 30.
    Freeman RB, Edwards EB, Harper AM. Waiting list removal rates among patients with chronic and malignant liver diseases. Am J Transpl. 2006;6:1416–1421.CrossRefGoogle Scholar
  31. 31.
    Merion RM, Schaubel DE, Dykstra DM, Freeman RB, Port FK, Wolfe RA. The survival benefit of liver transplantation. Am J Transpl. 2005;5:307–313.CrossRefGoogle Scholar
  32. 32.
    Elwir S, Lake J. Current status of liver allocation in the United States. Gastroenterol Hepatol (NY) [Internet]. 2016;12:166–170.Google Scholar
  33. 33.
    Massie AB, Chow EKH, Wickliffe CE, et al. Early changes in liver distribution following implementation of Share 35. Am J Transpl. 2015;15:659–667.CrossRefGoogle Scholar
  34. 34.
    Edwards EB, Harper AM, Hirose R, Mulligan DC. The impact of broader regional sharing of livers: 2-year results of “share 35”. Liver Transpl. 2016;22:399–409.CrossRefGoogle Scholar
  35. 35.
    Northup PG, Intagliata NM, Shah NL, Pelletier SJ, Berg CL, Argo CK. Excess mortality on the liver transplant waiting list: Unintended policy consequences and model for end-stage liver disease (MELD) inflation. Hepatology. 2015;61:285–291.CrossRefGoogle Scholar
  36. 36.
    Massie AB, Caffo B, Gentry SE, et al. MELD exceptions and rates of waiting list outcomes. Am J Transpl. 2011;11:2362–2371.CrossRefGoogle Scholar
  37. 37.
    Roberts JP, Venook A, Kerlan R, Yao F. Hepatocellular carcinoma: ablate and wait versus rapid transplantation. Liver Transpl.. 2007;13:465–466.Google Scholar
  38. 38.
    Pompili M, Francica G, Ponziani FR, Iezzi R, Avolio AW. Bridging and downstaging treatments for hepatocellular carcinoma in patients on the waiting list for liver transplantation. World J Gastroenterol. 2013;19:7515–7530.CrossRefGoogle Scholar
  39. 39.
    OPTN. HCC policy changes affect applications for non-automatic exception requests [Internet]. HRSA. 2015. Available from: https://optn.transplant.hrsa.gov/news/hcc-policy-changes-affect-applications-for-non-automatic-exception-requests/.
  40. 40.
    OPTN/UNOS. OPTN/UNOS policy notice modification to hepatocellular carcinoma (HCC) extension criteria. 2018.Google Scholar
  41. 41.
    Heimbach JK, Hirose R, Stock PG, et al. Delayed hepatocellular carcinoma MELD exception score improves disparity in access to liver transplant in the US julie. Hepatology. 2015;61:1643–1650.CrossRefGoogle Scholar
  42. 42.
    Yao FY, Mehta N, Flemming J, et al. Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria. Hepatology. 2015;61:1968–1977.CrossRefGoogle Scholar
  43. 43.
    OPTN/UNOS. Liver review board guidance documents liver review board guidance documents. 2017.Google Scholar
  44. 44.
    Hameed B, Mehta N, Sapisochin G, Roberts JYF. Alpha-fetoprotein level > 1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the milan criteria. Liver Transpl. 2007;13:465–466.Google Scholar
  45. 45.
    Soriano A, Varona A, Gianchandani R, et al. Selection of patients with hepatocellular carcinoma for liver transplantation: past and future. World J Hepatol. 2016;8:58–68.CrossRefGoogle Scholar
  46. 46.
    Biggins SW, Kim WR, Terrault NA, et al. Evidence-based incorporation of serum sodium concentration Into MELD. Gastroenterology. 2006;130:1652–1660.CrossRefGoogle Scholar
  47. 47.
    Biggins SW, Rodriguez HJ, Bacchetti P, Bass NM, Roberts JP, Terrault NA. Serum sodium predicts mortality in patients listed for liver transplantation. Hepatology. 2005;41:32–39.CrossRefGoogle Scholar
  48. 48.
    Kim WR, Biggins SW, Kremers WK, et al. Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med [Internet]. 2008;359:1018–1026.CrossRefGoogle Scholar
  49. 49.
    Trotter JF, Brimhall B, Arjal R, Phillips C. Specific laboratory methodologies achieve higher model for endstage liver disease (MELD) scores for patients listed for liver transplantation. Liver Transpl. 2004;10:995–1000.CrossRefGoogle Scholar
  50. 50.

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Center for Liver DiseasesUniversity of Chicago MedicineChicagoUSA
  2. 2.Department of Internal MedicineUniversity of Chicago MedicineChicagoUSA

Personalised recommendations